IVAC MUTANOME Phase I Clinical Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02035956|
Recruitment Status : Active, not recruiting
First Posted : January 14, 2014
Last Update Posted : November 14, 2018
|Condition or disease||Intervention/treatment||Phase|
|Melanoma||Biological: IVAC MUTANOME, RBL001/RBL002||Phase 1|
IVAC MUTANOME is a poly-neo-epitopic coding RNA vaccine targeting the unique mutation signature of an individual patient. It is engineered on demand, provided as two patient-specific RNA drug products and administered as an individual treatment.
RBL001/RBL002 and IVAC MUTANOME are naked ribonucleic acid (RNA) based recombinant vaccines optimized to induce antigen-specific CD8+ and CD4+ T cell responses against melanoma associated target antigens.
The two antigens are well characterized antigens in melanoma that have been previously utilized with excellent safety and proven immunogenicity as vaccine targets in a number of independent clinical trials.
The overall rationale of the study is to determine safety of the novel RNA-based vaccine strategy and determine the number and function of vaccine-induced antigen-specific immune-responses as early biomarkers for the clinical mode of action.
The IVAC MUTANOME vaccine approach is based on targeting multiple immunogenic tumour mutations unique to a given patient's tumour using a poly-epitopic RNA-based vaccine manufactured for use in a single patient only. Parallel to the target discovery process and on demand manufacturing of IVAC MUTANOME vaccine patients with RBL001 and/ or RBL002 positive-tumours will receive the RBL001/RBL002 vaccine. Patients which tumours that are RBL001 and RBL002 negative can also be included into the clinical study but will not receive RBL001/RBL002 prior to IVAC MUTANOME. Applying this approach the RBL001/RBL002 vaccine and the IVAC MUTANOME vaccine administration is expected to lead to several effects contributing to their immunological (therapeutic) effects.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma|
|Actual Study Start Date :||December 2013|
|Actual Primary Completion Date :||February 14, 2017|
|Estimated Study Completion Date :||March 2019|
Experimental: IVAC MUTANOME RBL001/RBL002
All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.
Biological: IVAC MUTANOME, RBL001/RBL002
Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
Other Name: cancer vaccine
- Safety and tolerability of repetitive doses [ Time Frame: up to a maximum of 189 days ]Number of Patients with adverse events, total number of adverse events
- Monitoring of vaccine-induced cellular immune response, [ Time Frame: 161 days ]Determination of pharmacodynamic activity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02035956
|Medizinische Universität Wien|
|Wien, AT-Wien, Austria, 1090|
|Hautklinik und Poliklinik Universitätsmedizin der Johannes-Gutenberg Universität Mainz|
|Mainz, Germany, 55131|
|Klinik für Dermatologie, Venerologie und Allergologie UMM - Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg|
|Mannheim, Germany, 68167|
|Study Director:||Ugur Sahin, Prof. Dr.||Biontech RNA Pharmaceuticals GmbH|